Researchers explore the impact of CD163-positive tumor-associated macrophages on the effectiveness of nivolumab in treating ...

Joseph Jacob, MD, discusses gemcitabine intravesical delivery as a highly effective treatment for high-risk, BCG-unresponsive bladder cancer, achieving an 82% response rate.

Zipalertinib demonstrates significant efficacy and manageable safety in treating EGFR exon 20 insertion-mutated NSCLC, ...

Joseph Jacob, MD, discusses the how the recent FDA approval of the gemcitabine intravesical system offers a radically different treatment approach for patients with bladder cancer.

Rezatapopt shows promising efficacy in treating various tumors with TP53 Y220C mutations, highlighting its potential as a ...

A new study reveals that pembrolizumab and bevacizumab offer a promising, less toxic treatment for recurrent ovarian cancer, especially the clear cell subtype.

Hardeep Phull, MD, director of oncology at Palomar Health, discusses the value of virtual health care and telehealth for both ...

Neoadjuvant darovasertib elicited strong antitumor activity, reduced simulated radiation doses, and lowered the risk of ...

Dordaviprone gains NCCN approval as a promising treatment for recurrent H3 K27M-mutant diffuse glioma, addressing urgent ...

Promising results emerge from a clinical trial combining IDE397 and Trodelvy for treating MTAP-deleted urothelial cancer, ...

Discover how AI transforms practice management by streamlining documentation, enhancing patient experiences, and optimizing ...

During a live event, Tejas Patil, MD, discussed outcomes from small cell lung cancer trials including the recent IMforte ...